PSMA and Beyond 2025 CAR-T and Bispecific antibodies targeting PSMA, Poseida trial, neuroendocrine prostate cancer, STEAP-1.

AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, ...

pasritamig, KLK2 T-cell engager, bispecific antibody prostate cancer, Phase I trial results, mCRPC immunotherapy, Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study with Capucine ...

Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.

The prevalence of kidney stone disease and associated events is rising, with modern surgical approaches emphasizing minimally invasive techniques like ambulatory percutaneous nephrolithotomy (PCNL).

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

Neeraj Agarwal speaks with Praful Ravi about an individual patient data meta-analysis examining docetaxel addition to ADT plus radiation therapy in high-risk localized prostate cancer. The ISECaP ...

Zachary Klaassen discusses the NureCombo Trial with Chiara Mercinelli, examining neoadjuvant therapy for muscle-invasive bladder cancer. This phase II trial investigated nab-paclitaxel plus nivolumab ...

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), SURE-01 trial, radical cystectomy, neoadjuvant sacituzumab govitecan (SG), monotherapy, sacituzumab govitecan followed by radical ...

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about ...